Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

[Preprint]. 2023 Nov 22:2023.06.14.544983. Originally published 2023 Jun 15. [Version 4] doi: 10.1101/2023.06.14.544983

PMC10312765.1; 2023 Jun 15
PMC10312765.2; 2023 Aug 23
PMC10312765.3; 2023 Oct 23
PMC10312765.4; 2023 Nov 22

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License, which allows reusers to copy and distribute the material in any medium or format in unadapted form only, and only so long as attribution is given to the creator. The license allows for commercial use.

PMC Copyright notice

Figure 5. — Comparative antimicrobial susceptibility profiles of hypermutators and normomutators in Patient 1 (A) and Patient 2 (B) as measured by zone of inhibition in a standard disc diffusion assay highlight increased sensitivities and resistance levels by hypermutators. (A) In Patient 1, hypermutators were significantly more resistant to amikacin (U = 315.5, p = .00013), piperacilin-tazobactam (U = 457.5, p = .023), and ceftazidime (U = 428, p = .0095) than normomutators, although there was no significant difference in the resistance profiles of hyper- and normomutators in regards to meropenem (U = 630, p =.69). Hypermutator isolates in Patient 1 displayed zone of inhibition (ZOI) values that were on average 10 times larger for ciprofloxacin (U = 218, p < .00001) and >13 times larger for tobramycin (U = 379.5, p = .0018) than normomutators, and isolates with both DNA MMR mutations in this population additionally presented ZOI values that were 36 times larger than normomutators for tobramycin (U = 172.5, p < .00001), indicating increased sensitivity displayed by hypermutators. (B) In Patient 2, hypermutators displayed increased susceptibility to amikacin (U = 479, p = .029), meropenem (U = 194, p < .00001), piperacilin-tazobactam (U = 121.5, p < .00001), and ciprofloxacin (U = 213.5, p < .00001) relative to normomutators. Hypermutators in Patient 2 were more resistant to ceftazidime (U = 417.5, p = .0045). There was no statistically significant difference between the tobramycin susceptibility profiles of hyper- and normomutators in this population (U = 634.5, p = .61). (*) indicates p ≤ .05, (**) indicates p ≤ .01, (***) indicates p ≤ .001, and (****) indicates p < .0001 in a Mann-Whitney U test. Clinical thresholds for resistance to amikacin, meropenem, piperacillin-tazobactam, ciprofloxacin, tobramycin, and ceftazidime as determined by the CLSI are 14, 15, 14, 18, 12, and 14 mm, respectively. Clinical thresholds for sensitivity to these antimicrobials are 17, 19, 21, 25, 15, and 18 mm, respectively.